Last reviewed · How we verify
Insulin Lispro Mix50
Insulin Lispro Mix50 is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.
Insulin Lispro Mix50 is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin Lispro Mix50 |
|---|---|
| Also known as | LY275585-50 |
| Sponsor | Eli Lilly and Company |
| Drug class | Insulin analog, rapid-acting (premixed formulation) |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin Lispro is a rapid-acting human insulin analog created by reversing the order of the last two amino acids (lysine and proline) of human insulin, allowing faster absorption and onset of action. Mix50 is a 50/50 premixed formulation combining 50% rapid-acting insulin lispro with 50% insulin lispro protamine suspension (intermediate-acting), designed to provide both mealtime and basal insulin coverage in a single injection. This combination mimics physiologic insulin secretion patterns in diabetic patients.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes (PHASE4)
- Comparison of Insulin Mix25 Versus Mix50 (PHASE4)
- A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus (PHASE4)
- Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics (PHASE3)
- Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Listro Mix 50/50® and Humalog Mix50/50® in Healthy Subjects (PHASE1)
- A Study of Insulin Lispro Mix in Type 2 Diabetic Asian Patients (PHASE4)
- Efficacy of Insulin Lispro Mix 50/50 Therapy (NA)
- The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Lispro Mix50 CI brief — competitive landscape report
- Insulin Lispro Mix50 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI